New CEO brings strategic vision to Houston co. advancing neurodegenerative disease treatments

Q&A

Coya Therapeutics appoints a new CEO to lead its innovative Alzheimer's treatment development efforts. Photo via LinkedIn

Coya Therapeutics has named a new CEO. As of Nov. 1, Arun Swaminathan replaced Co-founder Howard Berman in the role. Berman has assumed the title of executive chairman, in which he will still remain active with the company.

Swaminathan started with Coya two years ago as chief business officer. This transition was planned, says the PhD-holding scientist and businessman.

“(Berman's) intent was that it was the right time to put in place a CEO that, as we move into the operational phases of the company, that can take the reins from him,” he tells InnovationMap.

Coya Therapeutics is a publicly traded biotechnology company that is working on two novel treatments for Alzheimer's disease. Coya's therapeutics, which are currently in trials, use regulatory T cells (T regs) to target both systemic- and neuroinflammation in patients.

InnovationMap: Berman has been a very visible CEO. Will you follow suit?

Arun Swaminathan: I think it's part of the CEO’s job to be visible and to communicate the value of our company to all the stakeholders out there. So yes, I do plan to be visible as well. Obviously, Howard as the founder had elements that he talked about, the foundational stories. I obviously will be doing less of that.

IM: What was your journey from the lab to the boardroom?

AS: I have a PhD from the University of Pittsburgh. I like to say that I grew up at Bristol Myers Squibb, so I started in a clinical pharmacology group at BMS, running clinical trials, but in the cardiovascular and metabolic space.

What happened was, as I was the study director on a diabetes trial there, and the data starts coming in for these early diabetic trials, and I got highly involved with the commercial folks at BMS in starting to plan out “What does the target profile look like? How is this going to play out in the real world?” You know, the marketing teams and commercial teams start engaging when clinical data is available, because they're starting to plan for the eventual launch of the product.

That gave me a lot of exposure to the commercial side of things, and I also got a lot of experience presenting to opinion leaders and others through that role. And I said, “What I really love is that intersection between science and business.” And so I think that was my moment.

Then I moved to business development and licensing, where I helped scan the universe for assets and talk to CEOs of companies like Coya as a junior person, trying to understand if there's something that we can bring into BMS to strengthen the pipeline of BMS. So that gave me exposure to deals, how deals are structured, how you negotiate a lot of that kind of stuff.

Then I said, “Look, if I want to be a complete person in biotech, I do need to go into more true commercial roles.” So I went into commercial strategy. I was involved in the commercial strategy for what is now known as Eliquis. Was back then known as apixaban. That’s still the generic name.

Then I led marketing for Orencia, a rheumatoid arthritis drug. So I went and got both strategic and tactical marketing experience at BMS, and then I used all of that experience, rounded up. I eventually ended up co-founding a company, and that's led me to the last nine years with smaller biotech companies. So that's my evolution and path. But I think my true moment of realization was about three years into my clinical role at BMS, when I said, what I really enjoy is translating good science into commercial value, and I think that's what excites me.

IM: Why is Houston an important part of Coya's success?

AS: It is important that Coya stays in Houston, because we have a very close association with Houston Methodist, we get a lot of our work, our early research work still done through Houston Methodist, through Dr. [Stanley] Appel's lab and through other experts. We absolutely have a special research agreement with Houston Methodist, so we have a very strong reason to be in Houston. So, we do not anticipate moving out of Houston.

------

This conversation has been edited for brevity and clarity.

From Your Site Articles
Coya Therapeutics rang the closing bell at Nasdaq last week, celebrating six months since its IPO, new data from trials, and additions to its team. Photo via LinkedIn

Houston company with revolutionary neurodegenerative disease treatment shares milestones since IPO

ring that bell

After announcing its initial public offering earlier this year, a Houston therapeutics company has celebrated the milestone and announced recent growth as well.

Coya Therapeutics (Nasdaq: COYA) rang the closing bell last week. The clinical-stage biotech company, which has developed a biologics therapy that prevents further spreading of neurodegenerative diseases by making regulatory T cells functional again, announced the closing of its $15.25 million IPO in January.

"We launched our IPO into one of the toughest biotech capital markets in recent memory and are enormously grateful to all our investors for the confidence they then showed in our prospects," says Howard Berman, CEO and chairman of Coya, in a June 12 letter to stockholders. "I believe that to date, we’ve executed strongly against the goals we then established, and I remain excited about our future."

In the letter, Berman shares some of the recent clinical successes from two treatments — COYA 302, a treatment for ALS, and COYA 301, a treatment for Alzheimer’s Disease. Both treatments have seen strong clinical proof of concept data in the respective open-label studies.

Earlier this year, Coya expanded its C-suite to include Dr. Arun Swaminathan as chief business officer. He has over 20 years of hands-on health care business executive experience. Prior to Coya, Swaminathan served in the same role for Actinium Pharmaceuticals.

"Arun is actively engaged in exploring potential strategic opportunities across our portfolio of assets as we believe successful partnering efforts have the potential to enhance our scientific bona fides, leverage our technology into new areas of unmet medical need, and importantly, possibly secure upfront fees and associated non-dilutive funding," Berman writes in the letter. "We look forward to pursuing additional value creation catalysts that further highlight our entrepreneurialism and ability to execute, while maintaining focus on our core assets."

The latest addition to the Coya team is Guillaume Dorothée, who joins the company's scientific advisory board. A leading expert on the role that the immune system and peripheral-central immune crosstalk play in the pathophysiology of Alzheimer's, he's a tenured research director and team head in neuroimmunology at the French National Institute of Health and Medical Research in Paris.

“I am glad and honored to join such eminent scientists on the prestigious SAB of Coya Therapeutics," he says in a June 5 statement from Coya. "I am fully convinced that innovative Treg-based immunomodulatory approaches, as developed by Coya, are highly promising therapeutic strategies for the treatment of neurodegenerative disorders and other neuroinflammatory conditions. I will be happy to help Coya Therapeutics in this exciting endeavor.”

Recently, Berman joined the Houston Innovators Podcast to discuss Coya's mission and plan post IPO.


For Howard Berman, CEO and co-founder of Coya Therapeutics, commercializing his company is personal. Photo courtesy of Coya

Why this Houston innovator is racing to commercialize its unique treatment for neurodegenerative diseases

HOUSTON INNOVATORS PODCAST EPISODE 182

When Howard Berman sought out renowned Houston Methodist researcher and neurologist Dr. Stanley Appel, he was looking for treatment for his father, who was suffering from dementia. He wasn't looking for a job, but Dr. Appel had other ideas and asked Berman to meet with him.

"I was interested in what I could do for my dad," Berman says on the Houston Innovators Podcast, explaining how he took the meeting with Dr. Appel, who then presented him with some of his research. "By slide five my jaw had hit the ground.

"He had shown that he could stop the progression in one of his early trials of ALS," Berman says.

Not too long after that meeting, Berman, who founded digital health platform imaware, joined Dr. Appel to lead commercialization of Coya Therapeutics, a biotech startup that raised over $20 million in venture funding before going public a few months ago.

Coya has developed a biologics therapy that prevents further spreading of neurodegenerative diseases by making regulatory T cells functional again. Diseases like ALS, the company's focus right now, prevent T-regs from doing their job in controlling inflammation, and without these cells hard at work, the human body doesn't stand a chance in fighting autoimmune threats.

Berman, as co-founder and CEO, has been at the helm of the company leading it through both the fundraising and IPO processes. Coya's IPO occured in a tough market — only 12 biotech companies went public last year, he explains. To Berman, that just proves how passionate the team was about getting this product to those who need it.

"It really says something for the fortitude and our team to come together to make it happen," he says on the show. "We're able to deliver and execute in a difficult market climate.

"Once you're a public company, you have different expectations," he continues. "But you also have the opportunity to go out and attract additional investors in ways you can't do as a private company."

For Berman, whose father passed away earlier this year, it's a personal motivation that drives him to lead the company — as well as an opportunity to advance the city of Houston.

"The next number of years as we develop this therapeutic regimen for ALS, we have the potential to transform Houston into something more than it is currently," he says. "Our success will be the city's success."

Berman shares more of the Coya Therapeutics story on the podcast, as well as how he sees Houston's potential as an emerging hub for biotech. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

2 leading Texas universities rank among world’s best for entrepreneurs

honor roll

The Lone Star State’s two biggest universities—the University of Texas at Austin and Texas A&M University—rank among the world’s best schools for entrepreneurs.

PitchBook’s annual list of the world’s top 100 universities for entrepreneurs takes into account both undergraduate and graduate programs. PitchBook analyzed more than 222,000 startup founders whose startups are VC-backed.

UT’s “unique” advantage

UT Austin landed at No. 10 on the list, down from No. 8 last year. PitchBook identified 1,002 UT-alumni founders at 948 startups. Collectively, those startups have raised $34.7 billion, according to PitchBook.

Among the 948 UT Austin-affiliated startups, these five have raised the most capital:

  • No. 1 Tucson, Arizona-based World View, $2.8 billion
  • No. 2 Austin-based Apptronik, $966 million
  • No. 3 Mountain View, California-based Lightmatter, $821 million
  • No. 4 Austin-based Function Health, $807 million
  • No. 5. San Francisco-based Niantic, $779 million

“The unique UT Austin advantage is the alignment between the university and the city,” Foundra.ai says. “Unlike schools where the campus ecosystem and the local startup scene are disconnected, Austin’s startup community actively recruits UT students and alumni, and UT programs actively send students into the local ecosystem.”

Texas A&M’s “living laboratory”

UT Austin’s biggest in-state rival, Texas A&M, appeared at No. 79 on the list, down from No. 76 last year. PitchBook tallied 317 A&M-alumni founders at 295 startups. Collectively, those startups have raised $9.8 billion, according to PitchBook.

Among the 317 A&M-affiliated startups, these five have raised the most capital:

  • No. 1 Austin-based RigUp, $817 million
  • No. 2 Austin-based ICON, $543 million
  • No. 3 Scottsdale, Arizona-based HomeLight, $413 million
  • No. 4 Everett, Washington-based Zap Energy, $326 million
  • No. 5 San Diego-based Splice Therapeutics, $320 million

A cornerstone of Texas A&M’s entrepreneurship offerings is the Center for Applied Entrepreneurship and Innovation at the Mays School of Business. The business school says the center “helps students explore, test, build, buy, and transform businesses in real markets.”

“Grounded in Texas as a living laboratory and guided by the Aggie core values, the center advances applied learning through industry engagement, AI-enabled experimentation, and collaboration across Mays and Texas A&M,” the business school says.

The most “exceptional” schools on PitchBook’s list

In announcing its rankings, PitchBook said: “Great entrepreneurs can come from anywhere, but some universities have a truly exceptional track record of attracting and producing future founders.”

The most exceptional universities, based on PitchBook’s criteria, are:

  • No. 1 University of California, Berkeley
  • No. 2 Stanford University
  • No. 3 Harvard University
  • No. 4 Cornell University
  • No. 5 Massachusetts Institute of Technology (MIT)

Planned KBR spinoff scores $1B NOAA deal for extreme weather forecasting

weather watch

Amid a major spinoff, Houston-based KBR's Mission Technology Solutions business has been awarded a five-year contract for up to $1.1 billion from NOAA’s National Weather Service to help predict and combat extreme weather conditions.

Under the follow-on Commercial Data Program National Mesonet Program (CDP NMP) contract, KBR will provide weather and observational data from commercial stations, university and research campuses, and other non-federal providers nationwide. The information collected will assist in predicting severe temperatures and high-impact weather conditions like extreme storms.

"This award underscores KBR's proven track record of delivering vital data that strengthens national forecasting capabilities," Todd May, KBR’s senior vice president of Mission Technology Solutions, said in a news release.

According to a separate release from NOAA, the contract expands upon KBR's existing relationship with the agency. KBR will work with about 70 private industry partners on services such as data recording, collection, aggregation and processing, and will lead the CDP NMP's "network of networks."

“NOAA gathers environmental information from a wide variety of sources, and a growing list of private industry partners have joined our agency to collect this vital data,” Ken Graham, director of NOAA’s National Weather Service, said in the release. “This agreement streamlines the process that turns raw data into the gold-standard forecasts that Americans depend on.”

KBR will utilize its Speed to Mission ImpactSM technology for the project to supply data from across regions, measurement types, and system configurations. Both KBR and NOAA say the expanded data collection contract will help the agency create more accurate and timely forecasts, particularly for severe weather and extreme events, while also creating a path for new weather-observation technologies.

KBR has supported the CDP NMP for more than 9 years. The program will be managed in Greenbelt, Maryland.

"We're driving expanded integration of commercial sensor and data sources into this platform and are honored to know our work helps forecasters give their communities earlier warnings and more time to prepare for dangerous weather,” May added in a release.

KBR’s Mission Technology Solutions business will be rebranded as Trinzic after its planned spin-off, the company announced last month. The spin-off is expected to close in January 2027.

Trinzic will work as an independent, publicly traded company focused on technology and engineering services for the space and national security sector. KBR will remain a separate publicly traded company that will focus on sustainable technology and services to support the energy transition.

This is the salary required to live comfortably in Texas in 2026

Money Matters

A new national report looking at the income it takes to live comfortably in each of the 50 states has revealed Texans need to earn slightly less now than a year ago.

SmartAsset analyzed what a single individual, as well as family of four, must earn to cover minimum basic needs adjusted using the 50/30/20 budgeting rule. The resulting estimate represents the annual, pre-tax income needed to live comfortably in every U.S. state.

A single, full-time worker needs to make $90,563 to live comfortably in the Lone Star State, the report found, which is down a meager 0.2 percent from last year ($90,771).

Under the 50/30/20 budgeting strategy, that means a single Texas earner would have $45,282 to spend on necessities like housing and utilities, $27,169 for discretionary spending, and $18,113 for emergencies or retirement savings.

Texas ranked 34th nationally in SmartAsset's list of states with the highest income needed for a single adult to live "in sustainable comfort" in 2026. Only five other states — Tennessee, Maryland, Louisiana, North Carolina, and Mississippi — saw a decline in the income needed to live comfortably this year.

For a family of four to live comfortably in Texas, income requirements change significantly, according to the findings. To support a two-child household, a family needs $203,424 in combined total household income to be considered financially stable. This is down slightly from 2025, when SmartAsset reported a family of four in needed $204,922 to live comfortably in Texas.

This is a comfortable lifestyle for a family of four in Texas, according to the report:

  • $101,712 dedicated to necessities and living expenses
  • $61,027 dedicated to discretionary spending
  • $40,685 dedicated to emergencies, savings, or debt repaymen

According to the report, a family of four now needs to make at least $200,000 to live comfortably in 40 U.S. states, a figure that is far out of reach for many American families.

"As housing, grocery, transportation and other essential costs pressure household budgets, earning a six-figure salary no longer guarantees financial comfort in much of the U.S.," the report said. "A single adult now needs at least $80,000 a year to live comfortably in every state, while the threshold exceeds $100,000 in nearly half of states. For a family of four, the income needed to live comfortably is as much as $329,000."

Still, earning the minimum income to live comfortably in Texas doesn't guarantee financial stability in the Lone Star State's major cities. Earlier this year, SmartAsset determined single residents in Houston need to make about $90,000 to qualify as financially stable, while families of four need around $205,000.

---

This article originally appeared on CultureMap.com.

View All Listings